Endsulin
Brian Kaspar currently serves as the Chief Scientific Officer at Insmed Incorporated, where innovative research focuses on technologies such as artificial intelligence-driven protein engineering and gene therapy. In addition to this role, Brian is a Board Member at AccuGen Group and Vinta Bio, and a Scientific Advisory Board Member and Board of Directors member at Endsulin. Brian co-founded Milo Biotechnology, a company dedicated to developing gene therapy treatments for muscular disorders. Brian's previous experience includes serving as Chief Scientific Officer and SVP at AveXis, Inc., where groundbreaking work was done on gene therapies for rare neurological genetic diseases. Brian's academic background includes a Ph.D. in Molecular Pathology from UC San Diego and a Bachelor of Science in Neurobiology and Neurosciences from the University of Illinois Urbana-Champaign, supplemented by a faculty position at the Research Institute at Nationwide Children's Hospital, focusing on neuromuscular and neurodegenerative diseases, as well as postdoctoral research at the Salk Institute for Biological Studies.
This person is not in any teams
Endsulin
Endsulin is a pre-clinical stage gene therapy company whose mission is to end insulin dependence for good and free people from being defined by diabetes. Our approach employs a widely studied and proven viral vector to deliver our patented genetic factor to the liver and restore the body’s own ability to produce and regulate insulin. With a single administration, Endsulin’s revolutionary genetic therapy for T1DM delivers a patented genetic factor that will “switch on” new insulin-producing cells to confer years – and perhaps a lifetime – of freedom from injecting artificial insulin, realizing the goal that has eluded researchers since the discovery of insulin. Founded by an award-winning transplant surgeon and world leader in diabetes care and supported by a team of experts in gene therapy, endocrinology, diabetes science, and pharmaceutical development, Endsulin has the scientific, medical, and commercial expertise to develop its innovative therapy quickly, filling an enormous unmet need and bringing us one step closer to ending insulin dependence for good — and for the good of everyone with T1DM.